Top

Published in:

01-06-2011

Implementing Sentinel Lymph Node Biopsy Programs in Developing Countries: Challenges and Opportunities

Authors: Mohammed Keshtgar, John J. Zaknun, Durre Sabih, Graciela Lago, Charles E. Cox, Stanley P. L. Leong, Giuliano Mariani

Published in: World Journal of Surgery | Issue 6/2011

Abstract

Background

Sentinel lymph node biopsy (SLNB) is the accepted standard of care in early-stage breast cancer and cutaneous melanoma. This technology is accurate for nodal staging and determining the prognosis of these patients. There are several randomized controlled trials confirming the accuracy of this technique and confirming its role in reducing morbidity and improving quality of life. It is also gaining increased acceptance in the management of other solid tumors. Despite the established benefits of SLNB as a minimally invasive approach for nodal staging, the procedure is still underutilized in many developing countries.

Methods

The Human Health Division of the International Atomic Energy Agency (IAEA) convened advisory meetings with panels of multidisciplinary experts from different backgrounds with the remit to analyze the difficulties encountered by developing countries in establishing a successful SLNB program. The other remit of the panel was to recommend an effective program based on existing evidence that can be adapted and implemented in developing countries. The experience of some members of the panel in the training for this technique in Asia, Latin America, and Africa provided the insight required for the development of a comprehensive and structured program. The panel included recommendations on the technical aspects of the procedure, as well as a comprehensive training program, including theoretical teaching, practical training in surgical skills, laboratories, and hands-on proctored learning. Particular emphasis was placed on in-built quality assurance requirements to ensure that this powerful staging investigation is implemented with the highest possible standard in the management of cancer patients, with the lowest false negative rate.

Conclusions

It is hoped that this article will be a useful resource for our colleagues planning to establish a SLNB program.

Curado MP, Edwards B, Shin HR et al (2007) Cancer incidence in five continents, vol IX. International Agency for Research on Cancer (IARC scientific publication no. 160), Lyon, France. http://www-dep.iarc.fr/

Peggy P (2008) “Westernizing” women’s risks? Breast cancer in lower-income countries. N Engl J Med 358:213–216CrossRef

Boyle P, Levin B (2008) World cancer report, World Health Organisation. International Agency for Research on Cancer, pp 412–417. Available at http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/index.php. Accessed 7 Jan 2011

Hoffman M, De Pinho H, Cooper D et al (2000) Breast cancer incidence and determinants of cancer stage in the Western Cape. S Afr Med J 90:1212–1216PubMed

Vorobiof D, Sitas F, Vorobiof G (2001) Breast cancer incidence in South Africa. J Clin Oncol 19(18 Suppl):125s–127sPubMed

Boyle P, Levin B (2008) World cancer report. World Health Organisation, International Agency for Research on Cancer, pp 408–411

Morton D, Cochran A, Thompson J (2008) The rationale for sentinel-node biopsy in primary melanoma. Nat Clin Pract Oncol 5:510–511PubMedCrossRef

Morton D, Wanek L, Nizze J et al (1991) Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 214:491–501PubMedCrossRef

Lyman G, Giuliano A, Somerfield M et al (2005) American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early stage breast cancer. J Clin Oncol 23:7703–7720PubMedCrossRef

10.

Bitten AJ (1999) Radiation detectors. In: Keshtgar M, Waddington W, Lakhani S (eds) The sentinel node in surgical oncology. Springer, Berlin, pp 19–33.

11.

Chiesa C, Toscano F, Mariani M et al (2007) Physical performance parameters of intraoperative probes. In: Mariani G, Giuliano AE, Strauss HW (eds) Radioguided surgery—a comprehensive team approach. Springer, New York, pp 12–22

12.

Kim T, Giuliano A, Lyman G (2006) Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a meta-analysis. Cancer 106:4–16PubMedCrossRef

13.

Veronesi U, Galimberti V, Mariani L et al (2005) Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. Eur J Cancer 41:231–237PubMedCrossRef

14.

Purushotham A, Upponi S, Klevesath M et al (2005) Morbidity after sentinel lymph mode biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 23:4312–4321PubMedCrossRef

15.

Mansel R, Fallowfield L, Kissin M et al (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst 98:599–609PubMedCrossRef

16.

Del Bianco P, Zavagno G, Burelli P et al (2008) Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the Sentinella-GIVOM Italian Randomised Clinical Trial. Eur J Surg Oncol 34:508–513PubMed

17.

Krag D, Anderson S, Julian T et al (2007) Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 Randomised Phase III Trial. Lancet Oncol 8:881–888PubMedCrossRef

18.

Gill G, The SNAC Trial Group of the Royal Australasian College of Surgeons (RACS), NHMRC Clinical Trials Centre (2009) Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol 16:266–275

19.

Naik A, Fey J, Gemignani M et al (2004) The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg 240:462–468 (discussion 468–471)PubMedCrossRef

20.

Veronesi U, Galimberti V, Paganelli G et al (2009) Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases. Eur J Cancer 45:1381–1388PubMedCrossRef

21.

Thompson J (2002) The Revised American Joint Committee on Cancer staging system for melanoma. Semin Oncol 29:361–369PubMedCrossRef

22.

Filippakis G, Zografos G (2007) Contraindications of sentinel lymph node biopsy: are there any really? World J Surg Oncol 5:10PubMedCrossRef

23.

Hatta N, Morita R, Yamada M et al (2005) Implications of popliteal lymph node detected by sentinel lymph node biopsy. Dermatol Surg 31:327–330PubMedCrossRef

24.

Morton DL, Cochran AJ, Thompson JF et al (2005) Sentinel node biopsy for early-stage melanoma accuracy and morbidity in MSLT-I, an International Multicenter Trial. Ann Surg 242:302PubMed

25.

Rossi C, De Salvo G, Trifiro G et al (2006) The impact of lymphoscintigraphy technique on the outcome of sentinel node biopsy in 1,313 patients with cutaneous melanoma: an Italian Multicentric Study (SOLISM-IMI). J Nucl Med 47:234–241PubMed

26.

Byrd-Miles K, Toombs E, Peck G (2007) Skin cancer in individuals of African, Asian, Latin American, and American-Indian descent: differences in incidence, clinical presentation, and survival compared to Caucasians. J Drugs Dermatol 6:10–16PubMed

27.

Ridgeway C, Hieken T, Ronan S et al (1995) Acral lentiginous melanoma. Arch Surg 130:88–92PubMed

28.

Phan A, Touzet S, Dalle S et al (2006) Acral lentiginous melanoma: a clinicoprognostic study of 126 cases. Br J Dermatol 155:561–569PubMedCrossRef

29.

Ishihara K, Saida T, Otsuka F et al (2008) Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol 13:33–41PubMedCrossRef

30.

Guggenheim M, Hug U, Jung F et al (2008) Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma. Ann Surg 247:687–693PubMedCrossRef

31.

Deo S, Samaiya A, Jain P et al (2004) Sentinel lymph node biopsy assessment using intraoperative imprint cytology in breast cancer patients: results of a validation study. Asian J Surg 27:294–298PubMedCrossRef

32.

Parmar V, Hawaldar R, Nadkarni MS et al (2009) Low axillary sampling in clinically node-negative operable breast cancer. Natl Med J India 22:234–236PubMed

33.

Waddington W, Keshtgar M, Taylor I et al (2007) Radiation safety of the sentinel lymph node technique in breast cancer. Eur J Nucl Med 27:377–391CrossRef

34.

Hoh C, Wallace A, Vera D (2003) Preclinical studies of [^99mTc]DTPA-mannosyl-dextran. Nucl Med Biol 30:457–464PubMedCrossRef

35.

Ellner S, Hoh C, Vera D et al (2003) Dose-dependent biodistribution of [^99mTc]DTPA-mannosyl-dextran for breast cancer sentinel lymph node mapping. Nucl Med Biol 30:805–810PubMedCrossRef

36.

Vera D, Wallace A, Hoh C (2001) [^99mTc]MAG(3)-mannosyl-dextran: a receptor-binding radiopharmaceutical for sentinel node detection. Nucl Med Biol 28:493–498PubMedCrossRef

37.

Vera D, Wallace A, Hoh C et al (2001) A synthetic macromolecule for sentinel node detection: ^99mTc-DTPA-mannosyl-dextran. J Nucl Med 42:951–959PubMed

38.

Derossis AM, Fey J, Yeung H et al (2001) A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer. J Am Coll Surg 193:473–478PubMedCrossRef

39.

McMasters KM, Tuttle TM, Carlson DJ et al (2000) Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 18:2560–2566PubMed

40.

Hung WK, Chan CM, Ying M et al (2005) Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer. Br J Surg 92:1494–1497PubMedCrossRef

41.

Morrow M, Rademaker AW, Bethke KP et al (1999) Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. Surgery 126:714–720PubMedCrossRef

42.

Keshtgar MRS, Ell PJ (2002) Clinical role of sentinel lymph node biopsy in breast cancer. Lancet Oncol 3:105–110PubMedCrossRef

43.

Morton DL, Thompson JF, Essner R et al (1999) Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 230:453–563PubMedCrossRef

44.

Fisher B, Jeong JH, Anderson S et al (2002) Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347:567–575PubMedCrossRef

45.

East JM, Valentine CSP, Kanchev E et al (2009) Sentinel lymph node biopsy for breast cancer using methylene blue dye manifests a short learning curve among experienced surgeons: a prospective tabular cumulative sum (CUSUM) analysis. BMC Surg 9:2PubMedCrossRef

46.

Ahmadzadehfar H, Habibi E, Biermann K et al (2007) Impact of injection for sentinel lymph node scintigraphy in breast cancer: is the quadrant of superficial tracer injection of importance? Eur J Nucl Med Mol Imag 34(Suppl 2):S225

47.

Bonadonna G, Valagussa P, Brambilla C et al (1993) Preoperative chemotherapy in operable breast cancer. Lancet 341:1485PubMedCrossRef

48.

Kilbride KE, Lee MC, Nees AV et al (2008) Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence. Ann Surg Oncol 15:3252–3258PubMedCrossRef

49.

Papa MZ, Zippel D, Kaufman B et al (2008) Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer. J Surg Oncol 98:403–406PubMedCrossRef

50.

Classe JM, Bordes V, Campion L et al (2009) Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol 27:726–732PubMedCrossRef

51.

Tausch C, Konstantiniuk P, Kugler F et al (2008) Austrian Sentinel Node Study Group. Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Study Group. Ann Surg Oncol 15:3378–3383PubMedCrossRef

52.

Viale G, Mazzarol G, Maiorano E (2007) Histopathology of sentinel lymph node. In: Mariani G, Giuliano AE, Strauss HW (eds) Radioguided surgery—a comprehensive team approach. Springer, New York, pp 190–194

53.

Amersi F, Giuliano A, Hoon D (2007) Molecular assessment of sentinel lymph nodes. In: Mariani G, Giuliano AE, Strauss HW (eds) Radioguided surgery—a comprehensive team approach. Springer, New York, pp 206–217

54.

Romanini A, Manca G, Pellegrino D et al (2005) Molecular staging of the sentinel lymph node in melanoma patients: correlation with clinical outcome. Ann Oncol 16:1832–1840PubMedCrossRef

55.

Ulrich J, Bonnekoh B, Bockelmann R et al (2004) Prognostic significance of detecting micrometastases by tyrosinase RT/PCR in sentinel lymph node biopsies: lessons from 322 consecutive melanoma patients. Eur J Cancer 40:2812–2819PubMedCrossRef

56.

Manzotti M, Dell’Orto P, Maiaonneuve P et al (2001) Reverse transcription-polymerase chain reaction assay for multiple mRNA markers in the detection of breast cancer metastases in sentinel lymph nodes. Int J Cancer 95:307–312PubMedCrossRef

57.

Gillanders W, Mikhitarian K, Hebert R et al (2004) Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study. Ann Surg 239:828–837 (discussion 837–840)PubMedCrossRef

58.

Nissan A, Jager D, Roystacher M et al (2006) Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients. Br J Cancer 94:681–685PubMed

59.

Mikhitarian K, Martin R, Mitas M et al (2005) Molecular analysis improves sensitivity of breast sentinel lymph node biopsy: results of a multi-institutional prospective cohort study. Surgery 138:474–481PubMedCrossRef

60.

Gimbergues P, Dauplat M, Cayre A et al (2007) Correlation between molecular metastases in sentinel lymph nodes of breast cancer patients and St Gallen Risk Category. Eur J Surg Oncol 33:16–22PubMed

61.

Chicken D, Kocjan G, Falzon M et al (2006) Intraoperative touch imprint cytology for the diagnosis of sentinel lymph node metastases in breast cancer. Br J Surg 93:572–576PubMedCrossRef

62.

Soo V, Shen P, Pichardo R et al (2007) Intraoperative evaluation of sentinel lymph nodes for metastatric melanoma by imprint cytology. Ann Surg Oncol 14:1612–1617PubMedCrossRef

63.

Nicosia S, Cox C (2007) Frozen section and imprint cytology in sentinel lymph node biopsy for breast cancer. In: Mariani G, Giuliano AE, Strauss HW (eds) Radioguided surgery—a comprehensive team approach. Springer, New York, pp 48–49

64.

Viale G, Mastropasqua MG, Maiorano E et al (2006) Pathologic examination of the axillary sentinel lymph nodes in patients with early-stage breast carcinoma: current and resolving controversies on the basis of the European Institute of Oncology experience. Virchows Arch 448:241–247PubMedCrossRef

65.

Viale G, Dell’Orto P, Biasi MO et al (2008) Comparative evaluation of an extensive histopathologic examination and a real-time reverse-transcription-polymerase chain reaction assay for mammaglobin and cytokeratin 19 on axillary sentinel lymph nodes of breast carcinoma patients. Ann Surg 247:136–142PubMedCrossRef

66.

Whitman E (2007) Training and credentialing for radioguided surgery. In: Mariani G, Giuliano AE, Strauss HW (eds) Radioguided surgery—a comprehensive team approach. Springer, New York, pp 45–54

67.

MacNeill F (2007) New start: the UK SLNB training programme—a progress report. Bull R Coll Surg Engl 89:60–68CrossRef

Title: Implementing Sentinel Lymph Node Biopsy Programs in Developing Countries: Challenges and Opportunities
Authors: Mohammed Keshtgar
John J. Zaknun
Durre Sabih
Graciela Lago
Charles E. Cox
Stanley P. L. Leong
Giuliano Mariani
Publication date: 01-06-2011
Publisher: Springer-Verlag
Published in: World Journal of Surgery / Issue 6/2011
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-011-0956-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Implementing Sentinel Lymph Node Biopsy Programs in Developing Countries: Challenges and Opportunities

Abstract

Background

Methods

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2011

Safety Measures During Cholecystectomy: Results of a Nationwide Survey

Transthoracic Versus Transhiatal Esophagectomy for Esophageal Carcinoma: Experience from a Single Tertiary Care Institution

Defining Decision Making: A Qualitative Study of International Experts’ Views on Surgical Trainee Decision Making

Quality of Care in Humanitarian Surgery

Potential Economic Benefit of Cleft Lip and Palate Repair in Sub-Saharan Africa

Ballistic Thoracoabdominal Injury: Analysis of Recent Military Experience in Afghanistan